Toward an AIDS-Free Generation
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SINCE THE FIRST CASES OF WHAT IS NOW KNOWN AS AIDS were reported in 1981, an entire generation has grown up under the constant cloud of this modern-day plague. Across the globe, more than 34 million people are living with the human immunodeficiency virus (HIV), the virus that causes AIDS, including approximately 1.2 million individuals in the United States. HIV/AIDS has been responsible for the deaths of an estimated 30 million individuals. Although the rate of new HIV infections has declined or stabilized in many countries, the disease continues to exact an enormous toll: 1.8 million deaths in 2010 alone, grief and hardship for countless families and communities, and deleterious economic effects as those in the prime of life who lack timely access to treatment are lost to parenting and the workforce. Depending on the region of the world, many die with little or no access to medical care, while others require and receive expensive medical and endof-life care. Despite these daunting statistics, the fight against HIV/AIDS is currently viewed with considerably more optimism than in years past because powerful interventions have been developed, scientifically proven effective, and refined. If these tools are made widely available to those who need them, an AIDS-free generation may be possible—that is, today’s children could one day live in a world in which HIV infections and deaths from AIDS are rare. Foremost among these interventions is combination antiretroviral therapy, which significantly improves the health and longevity of individuals infected with HIV. Since the advent of antiretroviral therapy, the annual number of deaths due to AIDS has decreased by two-thirds in the United States. Globally, an estimated 700 000 lives were saved in 2010 alone due to the increased availability of antiretroviral therapy in lowand middle-income countries. Important challenges remain—notably finding the resources and developing the infrastructure to provide antiretroviral therapy to the estimated 8 million individuals with HIV infection who need these drugs but are not receiving them. Moreover, in wealthy and lower-income countries, only a minor proportion of those with HIV can navigate the entire HIV care cascade, from testing and diagnosis to accessing and being retained in care, starting antiretroviral therapy at the appropriate time, and then adhering to prescribed regimens to adequately suppress the viral load. Resources and innovative strategies are essential to find, test, and counsel those with HIV infection; help them remain in care; and derive the maximal benefit from antiretroviral therapy and other HIV/AIDS– related services. Importantly, antiretroviral therapy can also prevent HIV infection by reducing the amount of virus in an infected person’s blood and other body fluids such as genital secretions, making it less likely that the virus will be transmitted to others. A pivotal clinical trial known as HPTN 052 demonstrated that when providing antiretroviral therapy to the infected partner in HIV-discordant heterosexual couples early in the course of disease, the risk of HIV transmission to uninfected partners is significantly reduced when compared with deferring therapy until the disease was more advanced. Modeling data and studies in communities in which antiretroviral therapy is widely available suggest that scaling up antiretroviral therapy for HIV-infected individuals likely will substantially reduce the incidence of HIV infection. Thus, it is imperative to strive for universal access to antiretroviral therapy, both to benefit individuals with HIV infection and to reduce the risk of their sexual partners becoming infected. Antiretroviral therapy also is highly effective in blocking mother-to-child HIV transmission and helped prevent more than 350 000 infant infections worldwide from 20052010. Still, 390 000 infants were infected with HIV in 2010. Clearly, efforts to test, counsel, and provide effective antiretroviral therapy regimens to pregnant women with HIV infection must be enhanced to benefit their health as well as that of their infants. Moreover, reducing HIV infections among reproductive-age women and meeting their family planning needs is essential to eliminate mother-to-child transmission of HIV altogether. In addition to medical and societal interventions, voluntary medical male circumcision—a simple surgical procedure—offers a highly effective and durable way to protect heterosexual men from HIV infection. In 3 large-scale studies conducted in Africa, this 1-time intervention reduced the risk of a man acquiring HIV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Gray, R., Kigozi, G., Kong, X., Ssempiija, V., Makumbi, F., Wattya, S., Serwadda, D., Nalugoda, F., Sewenkambo, N. K., & Wawer, M. J. (2012) · AIDS · doi:10.1097/qad.0b013e3283504a3f · Cited by 209
HIV reservoirs: pathogenesis and obstacles to viral eradication and cure
Chun, T.-W., & Fauci, A. S. (2012) · AIDS · doi:10.1097/qad.0b013e328353f3f1 · Cited by 175
Self-citation
Cited by
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
The Syndemic Illness of HIV and Trauma: Implications for a Trauma-Informed Model of Care
Brezing, C., Ferrara, M., & Freudenreich, O. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.10.006 · Cited by 201
Higgs, E. S., Goldberg, A. B., Labrique, A. B., Cook, S. H., Schmid, C., Cole, C. F., & Obregón, R. A. (2014) · Journal of Health Communication · doi:10.1080/10810730.2014.929763 · Cited by 124
Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E. (2020) · Molecules · doi:10.3390/molecules25061338 · Cited by 19
Metadata
- Authors
- Fauci, A. S., & Folkers, G. K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-07-25
- Volume
- 308
- Issue
- 4
- Pages
- 343
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2083079333
- Cited by
- 86
- References
- 3
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.